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ABSTRACT 
The fast appearance of benzodiazepine analogues, referred to as new psychoactive substance 
(NPS) or designer benzodiazepines, requires the continuous update of detection methods in 
order to keep up with the latest drugs on the recreational drug market. Moreover, as usually 
only limited information on toxicity and excretion patterns of these new drugs exists, this 
needs to be evaluated to report on adverse effects and to determine suitable targets for drug 
testing.  
Urine drug testing usually involves screening using immunoassay followed by confirmation 
of positive screening results using mass spectrometric (MS) methods. We studied the 
detectability of designer benzodiazepines in urine using commercial immunoassays and 
demonstrated that most designer benzodiazepines can be detected by immunoassay. It is thus 
important to update confirmation methods to include designer benzodiazepines. We also 
developed a liquid chromatographic–tandem MS (LC–MS/MS) confirmation method for 
designer benzodiazepines in urine using direct dilution of samples and hydrolysis of 
conjugates. Subsequently, a further improved screening and confirmation method using LC–
high-resolution MS (LC–HRMS(/MS)) was developed. HRMS screening is performed in full 
scan and is a generic method that can easily include new analytes. LC–HRMS/MS 
confirmation only requires re-injection of the sample.  
Many samples from drug dependent patients with a positive immunoassay screening result 
for benzodiazepines but not containing prescription medicines detected a designer 
benzodiazepine instead. Comparable results were obtained for acute intoxication cases from 
emergency wards in the STRIDA project. In total, 28 designer benzodiazepines were covered 
by the analytical method and 17 of these were detected in the samples. Classification of a 
designer benzodiazepine as a narcotic substance generally meant that it was removed from 
the NPS market and replaced with another novel benzodiazepine. It was further demonstrated 
that intoxications by designer benzodiazepines might cause central nervous system 
depression.  
Studies on metabolic patterns of five designer benzodiazepines using urine samples from 
confirmed intoxication cases identified suitable analytical targets for urine drug testing, 
instead of or together with the parent compounds and both with and without hydrolysis of 
conjugated forms.  
In summary, the results demonstrated frequent use of designer benzodiazepines in Sweden 
and in cases of acute intoxication that they might cause serious adverse effects. This 
underlines the importance of including designer benzodiazepines and/or metabolites thereof 
in drug testing. Screening for designer benzodiazepines can be performed by immunoassay or 
LC–HRMS, and confirmation methods can make use of direct dilution of urine samples 
followed by hydrolysis and direct injection into LC–MS or LC–HRMS systems.  
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1 BACKGROUND 
In 2015, around 29.5 million people world-wide were estimated to suffer from illicit drug use 
that required treatment [1]. Such abuse has a large impact on society and the individual, with 
e.g. associated health problems and complications at the workplace [2]. Treatments for 
substance abuse problems can be both psychosocial and pharmacological and drug testing 
can be used as a valuable tool for detection and monitoring treatment progress. 
1.1 DRUG TESTING 
Drug testing can be performed using different matrices, e.g. blood, breath, hair, oral fluid and 
urine. Urine has become widely used for drug testing purposes and testing is first performed 
using screening (commonly by immunochemical methods) followed by confirmation with a 
more selective method (e.g. mass spectrometry). Drug testing is usually focused on traditional 
drugs of abuse but as of a few years back additional testing has become increasingly 
important due to the introduction of a large amount of new substances of abuse into the 
recreational drug market [3].  
1.2 THE NEW PSYCHOACTIVE SUBSTANCE (NPS) PHENOMENOM 
Violation of the law by distributing, manufacturing or possessing a narcotic substance can 
result in long prison sentences. To circumvent the risk of penalty, substances with structures 
similar to drugs classified as narcotic substances (e.g. amphetamine, benzodiazepines, 
cocaine, heroin) have been synthetized [4]. Due to this modification they usually have similar 
effects, but can be sold legally in many countries [4]. The European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) refer to these analogs as new psychoactive 
substances (NPS) with the definition that such substances include “a new narcotic or 
psychotropic drug, in pure form or in preparation, that is not controlled by the United Nations 
drug conventions, but which may pose a public health threat comparable to that posed by 
substances listed in these conventions” [5].  
In order to monitor the appearance of such structural variants, EMCDDA started to register 
these substances in the European Union Early Warning System. This system has registered 
>600 substances and >70% of them were added to the list during the past 5 years, with 
benzodiazepines and opioids increasing more and more (Figure 1) [3]. Around 20 
benzodiazepines were monitored by the EMCDDA in 2016, with 6 new reported in 2016 
alone (Figure 1) [3]. The large rise in NPS has become a challenge for drug testing 
laboratories since detection methods have to keep up with the latest drugs on the market. To 
confirm intake of a new drug, comparison with a reference material of this drug is usually 
needed. Due to the fast turn-over of these new drugs, such material is rarely present until just 
before the drug is replaced by another analogue of the classical drug. Furthermore, detection 
of NPS in biological samples is also complicated by the fact that little is usually known about 
their excretion patterns in humans [6].  
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Figure 1: Number of new psychoactive substances reported to the EU Early Warning system 
from 2005 to 2016. The number of newly reported benzodiazepines (purple) have increased 
steadily since 2011, with six new registered in 2016 (re-print from [3] with permission). 
 
Another issue with NPS is that as most of them have not been tested on humans before their 
appearance onto the recreational drug market nothing is known about their adverse effects 
[4]. Furthermore, NPS are commonly synthetized in clandestine laboratories with poor 
quality controls where contaminants and differences in doses may be found in the “products”, 
thus increasing the risk for adverse effects [4]. A substance where several severe intoxications 
have been noted is 3,4-methylenedioxypyrovalerone (MDPV) [7], which was banned by the 
European Union (EU) in 2014 and as a result is illegal to manufacture or market within the 
EU [8]. Other bans have been implemented in an attempt to reduce the number of NPS 
appearing on the recreational drug market [8]. These bans consist of countries amending their 
laws on controlled substances to include either a generic control (control of a substance 
cluster), analogue control (control of all substances with “chemical similarities” to listed 
substances) and individual listing (only control of listed substances) [8]. Currently, Sweden 
has the individual listing system and several substances included in this list are 
benzodiazepines (referred to as either designer or NPS benzodiazepines) [9].  
  3 
1.3 BENZODIAZEPINES AND DESIGNER BENZODIAZEPINES 
Benzodiazepines are drugs used to treat anxiety, insomnia and epilepsy [10]. Prescription 
frauds of these drugs are common in Europe [11] and a number of studies have shown that 
these drugs are commonly abused [12]. Furthermore, benzodiazepines are in many cases 
abused simultaneously with other substances, e.g. opioids to increase the effects of the 
opioids [12].  
The designer/NPS benzodiazepines are structural variants of prescription benzodiazepines 
and throughout this thesis all benzodiazepines currently not used as pharmaceuticals in 
Sweden are referred to as “designer benzodiazepines”. We have chosen this definition since 
Sweden has added several benzodiazepines to their narcotics list in the past few years and 
also since phenazepam was recently added as a substance in the Convention on Psychotropic 
Substances of 1971 [13], thus complicating the designation.  
1.4 METABOLISM 
The disposition of drugs within the body can be divided into four phases: absorption from site 
of administration, distribution within the body, metabolism and excretion/elimination [10]. 
Metabolism is the step in which the drug is modified to become more easily eliminated [10]. 
Due to this, urine usually only contains small amounts of unchanged drug. Consequently, 
bioanalytical methods for measurements in urine require measurement of metabolites and/or 
very low detection limits of the parent compound.  
Metabolism of benzodiazepines generally consist of two steps; oxidation and glucuronidation 
[14]. Additionally, other important steps include N-demethylation and for benzodiazepines 
containing a NO2 group, as in the case of flunitrazepam, nitro reduction [14, 15] followed by 
acetylation [15]. These previously mentioned metabolic steps have also been detected for 
designer benzodiazepines (Paper IV, V) [16-27]. 
Demethylation, oxidation and reduction steps are referred to as phase I (or functionalization) 
reactions since a new functional group is added to the drug [28]. It is apparent from the 
benzodiazepines reported in a review on their metabolism [14] that the cytochrome P450 
(CYP) enzymes are important metabolizing enzymes for the phase I reactions of 
benzodiazepines. The highest amount of CYP enzymes can be found in the liver and due to 
the large amount of different isoenzymes, a classification system depending on “family”, 
“subfamily” and individual gene has been applied [29]. This system is used to describe the 
isoenzyme responsible for a certain metabolic reaction and some that are important in human 
drug metabolism include CYP2C19, CYP2D6 and CYP3A4 [29].  
Acetylation, glucuronidation and sulfation are instead referred to as phase II (or conjugation) 
reactions [28]. These reactions are performed by acetyltransferases, UDP-
glucuronyltransferases (UGTs) and sulfotransferases (SULTs), respectively [28].  
Inter-individual differences can be found in the metabolism of drugs and these differences 
can depend on genetics (polymorphism) or environmental factors (inhibition or reduction of 
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the enzyme responsible for the metabolic reaction due to the presence of another compound) 
[10]. Thus, inter-individual differences in metabolic patterns needs to be taken into 
consideration when developing bioanalytical methods for detection of NPS to select the 
optimal bioanalytical targets.  
1.5 METHODS FOR ANALYZING DRUGS OF ABUSE 
Immunochemical assays have the advantage of being performed on high capacity automated 
analyzers that can include a large panel of tests. Disadvantages include poor specificity and 
target of substance classes rather than a specific compound for many assays, thus making it 
difficult to determine the drug ingested [30]. Due to this, as previously mentioned, drug 
testing is a two-step process usually involving screening with an immunochemical assay 
followed by confirmation with a more specific methodology e.g. mass spectrometry (MS) 
[31]. However, due to the high number of emerging NPS, high resolution mass spectrometry 
(HRMS) methods are preferred for screening since it is faster to include new substances with 
this technique compared to commercial immunoassays [32].  
For detection of benzodiazepines in biological samples, the use of liquid chromatography-
mass spectrometry (LC–MS) has increased [33]. Although chromatographic separation 
methods (LC more than gas chromatography (GC)) are most common, other techniques (e.g. 
capillary electrophoresis, capillary electrochromatography) have also been applied [33]. 
Many of these separation techniques have also been utilized in recently published articles for 
detection of designer benzodiazepines in biological samples [19, 22, 24-26, 34-42].  
1.5.1 Immunochemical assays 
As previously mentioned, immunochemical assays are usually used for drug screening. In 
Paper I we investigated the detectability of designer benzodiazepines using commercially 
available immunoassays. The techniques used are described below. 
1.5.1.1 Cloned Enzyme Donor Immunoassay (CEDIA), Enzyme Multiplied Immunoassay 
Technique (EMIT) and Homogenous Enzyme Immunoassay (HEIA) 
In EMIT [30] and HEIA [43], if a drug is present in the patient sample, both the drug present 
in the sample and the enzyme-labeled drug can bind to an antibody (Figure 2) [30, 43]. The 
enzyme-labeled drug not bound to the antibody can then react with the substrate and produce 
a product with an absorbance at a certain wavelength, resulting in an increased absorbance 
[30]. On the other hand, if the drug is not present in the investigated patient sample, the 
enzyme-labeled drug binds to the antibody, resulting in an inability of the enzyme to cleave 
the substrate (Figure 2) [30, 43]. Consequently, a lower absorbance is observed.  
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Figure 2: Principle of the homogenous enzyme immunoassay (HEIA) and enzyme multiplied 
immunoassay technique (EMIT).  
 
The CEDIA technique uses the same principle as EMIT and HEIA, but with two inactive 
enzyme fragments (a drug labeled enzyme donor, ED and an enzyme acceptor, EA) [30]. 
When ED binds to EA an active enzyme is formed. The active enzyme can cleave a substrate, 
in turn forming a product that absorbs light. As a result, if drug is present in the patient 
sample an increase in absorbance will be observed, otherwise a lower response will be 
detected [30].  
1.5.1.2 Kinetic Interaction of Microparticle in Solution (KIMS) 
The principle of KIMS is that if the drug is not present in a patient sample when measured 
using KIMS, an antibody will bind to a drug labeled microparticle, resulting in aggregate 
formation and an increase in absorbance [30]. However, if the drug is present in the patient 
sample, both the drug present in the sample and the drug labeled microparticle can bind to the 
antibody. Thus, the drug labeled microparticles that are not bound to the antibody cannot 
form aggregates and there will be a decrease in absorbance [30]. 
1.5.2 Sample preparation and separation techniques 
Before instrumental analysis a sample must be prepared with a suitable procedure. The 
sample preparation step must either separate components in a sample because of a more 
unselective detection (e.g. UV) or transfer the compound of interest from the biological 
matrix to a suitable extract. A common sample preparation procedure is liquid-liquid 
extraction, which uses a mixture of two different solvents to separate the compound of 
interest from matrix components [44]. Another extraction technique is solid phase extraction 
(SPE). In SPE the biological fluid is added to a cartridge containing a solid phase that adsorbs 
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components in the sample. This is followed by the addition of a liquid to wash out 
interferences in the sample and finally an additional liquid is added to elute the compounds of 
interest. These two extraction techniques have the advantage of achieving a sample clean up 
and also enables enrichment of the analytes to increase sensitivity. A faster alternative is to 
add e.g. an organic solvent or an acid to the biological samples to precipitate proteins present 
(e.g. plasma proteins), then centrifuge the samples and inject the supernatant into the 
separation system [44]. 
For urine samples, an alternative to extraction, that has been possible due to the combination 
of ultra high performance liquid chromatography (UHPLC) columns with a high separation 
efficiency and highly selective detection techniques, is to simply dilute the sample and inject 
it into the UHPLC–MS/MS system. A recent review demonstrated the application of dilution 
of samples combined with LC–MS in drug testing [45]. Authors pointed out the possibility of 
using this combination to develop fast, simple methods including substances with a larger 
variety in polarity as compared to GC-MS [45]. 
The chromatographic separation of components present in a sample is achieved by 
differences in distribution between a mobile phase and a stationary phase [44]. When GC is 
applied, the liquid sample is vaporized in the injector and then transported into the separating 
column using a carrier gas (mobile phase). Derivatizations are often performed to increase the 
thermostability and volatility of analytes but it should be noted that in many cases, the 
optimization and utilization of these derivatization procedures can be time consuming [44]. 
In LC, the mobile phase is a liquid phase. The most common LC separation mode is the 
“reversed phase”, in which the stationary phase is non-polar (e.g. octadecylsilane/C18 ) and 
the mobile phase is polar [44]. The polar mobile phases generally include a buffer and an 
organic solvent that is miscible with water (e.g. acetonitrile, methanol). The separation is 
performed using either a constant mixture of the components in the mobile phase (isocratic 
elution) or a mixture that is changed during the chromatographic run (gradient elution). The 
latter is usually used in multi-methods that include analytes with a large variety in polarity in 
order to optimize the analysis time [44]. An advantage of using the reversed phase mode is 
that polar liquids (e.g. diluted urine) can be directly injected into the LC system. 
A major progress in LC analysis was the introduction of UHPLC. In UHPLC it is possible to 
perform the separations with stationary phases of smaller particle sizes (that gives a higher 
separation efficiency) due to instrumentation that allows for a higher back-pressure [46]. An 
additional LC technique that required amendment of instrumentation is nano-LC [47]. Nano-
LC includes columns with a more narrow inner diameter, thus enhancing the sensitivity of the 
separations due to less bandbroadening [48]. 
1.5.3 Mass spectrometry (MS) 
For LC–MS analysis, the investigated compounds are present in the liquid phase when 
exiting the LC column, and the analytes need to be converted into the gas phase before 
entering the high vacuum inside the MS [49]. This conversion is performed in the interface 
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between the mass spectrometer and the LC. In the MS the ions are separated according to 
mass/charge (m/z) ratios and their intensities are recorded using a detector.  
A common interface used in LC–MS analysis is electrospray ionization (ESI). ESI is an 
ionization process where a liquid is sprayed from a capillary tube (where charges are picked 
up from an added potential over the capillary) following the addition of a heated gas resulting 
in evaporation of the spray into smaller droplets [49]. These droplets are then additionally 
broken down by evaporation which causes an even smaller droplet size (Figure 3). This 
process continues and finally, desorption of charged molecules occurs (Figure 3) [49]. 
Furthermore, when no sample clean-up is performed (as in the direct dilution approach), the 
amount of substances competing for charges increase resulting in a lower ionization 
efficiency for some compounds [45]. This difference in ionization efficiency is known as 
matrix effect and needs to be carefully validated. 
 
Figure 3: Evaporation of droplets to desorbed ions in electrospray ionization (all ions are 
drawn as MH
+
 ions for simplicity, however other adducts e.g. Na
+
 are also possible).  
 
One way of increasing the selectivity and sensitivity in MS methods is to use triple 
quadrupole instruments in tandem mass spectrometry (MS/MS) mode. The triple quadrupole 
mass spectrometer is a low unit resolution mass spectrometer consisting of three quadrupole 
analyzers (Q1–Q3) connected together in a sequence (Figure 4) [49]. 
 
Figure 4: Schematics of a triple quadrupole mass spectrometer showing the travel directions 
of the ions. 
 
Each quadrupole consists of four rods to which potentials are applied. In MS/MS mode, ions 
generated from the ion-source travel to the first quadrupole where, due the generated electric 
field in the quadrupole, only ions of a selected m/z ratio will pass through to the second 
quadrupole [49]. This selection is the result of ions with a selected m/z ratio being drawn 
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towards the charged rods without touching the rods since the potential of the rods are 
interchanging. The second quadrupole contains an inert collision gas that can collide with the 
ions supplied from the selection in the first quadrupole, which then allows for fragmentation 
of the ions. These fragmented ions are thereafter introduced into the third quadrupole where a 
selection according to m/z is performed in the same manner as in the first quadrupole [49]. As 
a result selective and sensitive methods can be developed since both the selection of ions with 
a certain m/z in Q1 and Q3 and the collision energy in Q2 can be optimized for a specific 
compound.  
A way to further increase the selectivity of MS methods is to use high resolution mass 
spectrometry (HRMS). The high resolving power of HRMS instruments allow determination 
of single elemental compositions, thus making them superior to triple quadrupole instruments 
in identification of unknown substances. A high resolution mass analyzer that was first 
described in 2000 but is now considered a “mainstream” mass spectrometer, is the orbitrap 
mass spectrometer [50]. These instruments consists of a C-trap that injects the ions into the 
orbitrap analyzer (Figure 5). Once the ions are injected into the orbitrap mass analyzer, they 
will start to oscillate around the central electrode due to a strong electrical field inside the 
orbitrap (Figure 5) [50]. The resulting current is then measured and transformed to 
frequencies and intensities of each m/z using Fourier transformation, resulting in the mass 
spectrum (Figure 5) [49]. The orbitrap has the advantage of yielding almost no background 
noise from other components present in the sample while on the other hand background noise 
can be found in TOF analyzers (another type of HRMS instrument), thus affecting the 
detection limits [51].  
 
Figure 5: Schematics showing the transfer of ions from the C-trap to the orbitrap mass 
analyzer where ions oscillate around the central electrode resulting in a current that is 
transformed into the mass spectrum using Fourier transformation. 
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1.6 METHODS FOR ASSESSING METABOLIC PATTERNS OF NPS 
Urine analysis of NPS is complicated since when NPS first appear on the drug market little or 
no knowledge regarding their excretion patterns in humans are known [6]. Consequently, it is 
essential to perform such studies in order to evaluate the metabolites present and to compare 
their presence in the sample with parent drug to determine analytical targets suitable for drug 
testing. An important factor in assessing the metabolic patterns of NPS is the limitations in 
performing controlled human studies due to ethical problems, and as a result several in vitro 
studies, animal studies, self-ingestion experiments and studies using samples from confirmed 
intoxication cases have been applied to circumvent this issue [6]. Many of these techniques 
have been utilized to determine the metabolic patterns of designer benzodiazepines (Paper 
IV, V) [16-27, 52]. 
1.6.1 In vitro studies 
In vitro studies have been performed using both subcellular fractions and intact hepatocytes 
[29]. Subcellular fractions include e.g. human liver microsomes (HLM) and human liver 
cytosols (HLC). HLM are prepared by breaking up eukaryotic cells and isolating certain 
enzymes by centrifugation, with the result of HLM present as sediments and HLC as 
supernatant. HLM include enzymes located at the endoplasmic reticulum such as CYPs and 
UGTs, while HLC instead includes soluble enzymes such as SULTs and catechol-O-
methyltransferase [29].  
Hepatocytes have the advantage of containing enzymes responsible for both phase I and II 
metabolism and co-substrates needed for metabolic reactions [29]. However, commercially 
available cryopreserved hepatocytes are more expensive and entail more complex 
incubation media compared to the subcellular fractions mentioned above [29]. Furthermore, 
enzyme activities can vary remarkably from lot to lot. 
1.6.2 In vivo studies 
In vivo studies to determine the excretion pattern of NPS in urine have included 
investigations of samples obtained from drug users, animal- and self-experiments [6]. These 
techniques have the advantage of representing living organisms as well as enabling collection 
of the biological matrix of interest [6].  
Animal experiments can be designed to mimic typical human doses [6]. On the other hand, as 
the excretion pattern may differ between humans and other animals, high dose investigations 
might be necessary. The higher dose would then increase the possibility to detect major 
human metabolites that are only present in low amounts in the animal when scaling to human 
doses is performed [6].  
In some countries, self-experiments are possible without ethical approval [16, 17, 19, 26, 52]. 
Here, the authors ingest the drug and then provide the biological samples for metabolism 
investigations. However, for the designer benzodiazepines, samples from such controlled 
studies have only been collected from one individual in each study [16, 17, 19, 26, 52], 
thereby potentially missing inter-individual differences in metabolic patterns. 
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Several NPS metabolism studies have been performed using samples obtained from drug 
users [6]. In these cases, urine metabolites can be corroborated by the presence of parent 
compounds in the urine (Paper IV, V) or by paired blood samples from the same patient. 
However, it is important to keep in mind the possibility of co-ingestions of structurally 
related compounds by the patient, making in vitro studies or animal studies good 
complements [6]. On the other hand, if samples are present from several patients, inter-
individual difference are more likely to be detected and thus the certainty for the suggested 
analytical targets increase.  
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2 AIMS 
The aims of this doctoral project were to: 
a) Investigate the detectability of designer benzodiazepines in urine using different 
bioanalytical techniques (immunochemistry and mass spectrometry) 
b) Investigate the occurrence of designer benzodiazepines in Sweden 
c) Determine the clinical characteristics of designer benzodiazepines from analytically 
confirmed intoxication cases 
The specific aims were: 
Paper I 
 To determine the detectability of designer benzodiazepines using commerically 
available immunoassays by determining cross-reactivities of parent compounds in 
spiked urine samples and by analyzing urine samples from intoxication cases 
Paper II 
 To develop and validate an LC-MS/MS method for detection of designer 
benzodiazepines in urine 
 To apply this method for analysis of patient urine samples to investigate occurrence of 
designer benzodiazepines in Sweden 
Paper III 
 To develop and validate an LC-HRMS method for detection of designer 
benzodiazepines in urine 
 To apply this method for analysis of patient urine samples to confirm method 
suitability 
Paper IV 
 To determine the human metabolic patterns of clonazolam, meclonazepam and 
nifoxipam and suggest metabolites suitable as targets for drug testing purposes 
Paper V 
 To determine the human metabolic patterns of flubromazolam and pyrazolam and 
suggest metabolites suitable as targets for drug testing purposes 
Paper VI 
 Study the occurrence of designer benzodiazepines in Sweden 
 Investigate the clinical features of designer benzodiazepines 
 Investigate the pattern of abuse among designer benzodiazepine users (in relation to 
multi-intoxications and time of national legislation) 
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3 MATERIALS AND METHODS 
3.1 STUDY SAMPLES 
The urine samples used for all studies were either de-identified aliquots collected from the 
routine drug testing service at the Department of Clinical Pharmacology, Karolinska 
University Laboratory originating from drug dependence clinics (ethical permit no. 00-230) 
or from the STRIDA project (ethical permit no. 2013/116-31/2). STRIDA 
(Samverkansprojekt avseende Toxicitetsutredning och Riskbedömning av InternetDroger 
baserat på kliniska Analyser) is a project that monitors the occurrence and health hazards of 
NPS in Sweden [53] with samples originating from patients presenting in emergency units 
all over Sweden.  
3.2 SAMPLE PREPARATION 
Urine samples were analyzed either directly (in all immunochemical assays) or after dilution 
(LC-MS analysis). The dilution applied for LC-MS analysis was performed either with 
(Paper I-III, V-VI) or without hydrolysis (Paper IV, V) of the samples. For hydrolysis, 170 
µL internal standard (IS) in 10 mmol/L ammonium acetate and 30 µL β-glucuronidase was 
added to 50 µL urine. When no hydrolysis was performed, urine samples were diluted 1:5 
with IS in 0.1% formic acid in Milli-Q water.  
3.3 INSTRUMENTATION 
The CEDIA, EMIT II Plus and HEIA immunochemical assays investigated were performed 
on an Olympus AU680 instrument (Beckman Coulter, Brea, CA, USA) and the KIMS II 
assay on a Cobas 6000 (c501) instrument (Roche Diagnostics, Mannheim, Germany). 
In Paper I and II an ACQUITY UPLC system with a Xevo TQ tandem mass spectrometer 
(Waters, Milford, MA, USA) operating in positive electrospray mode was used. Additionally, 
in Paper I and III-VI, an UHPLC-HRMS system (Dionex Ultimate UHPLC System 
coupled to a Q-Exactive system equipped with a heated electrospray ionization (HESI)-II 
source (Thermo Scientific, Waltham, MA, USA)) was utilized. Apart from the UHPLC-
HRMS system mentioned above, Paper IV also used an EASY-nLC system coupled to a Q-
Exactive equipped with an EASY-Spray source (Thermo Scientific). 
3.4 VALIDATION 
The method developed in Paper II was validated with the EMA guideline [54] using the 
following parameters: accuracy and precision, carry-over, dilution integrity, linearity, limit of 
detection (LOD), lower limit of quantification (LLOQ), matrix effects, selectivity and 
stability. These parameters (apart from dilution integrity) were also validated in Paper III but 
using an in-house guideline instead. The validation performed in Paper IV included 
investigation of intra accuracy and precision, LLOQ, LOD, matrix effect and selectivity and 
was less extensive compared to Paper II-III as the focus of Paper IV was the metabolism 
studies.  
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4 RESULTS AND DISCUSSION 
The analytical work used four immunochemical assays (CEDIA, EMIT II Plus, HEIA and 
KIMS II), a triple quadrupole mass spectrometry method and several orbitrap mass 
spectrometry methods in order to gain knowledge on the detectability, occurrence and 
metabolic patterns of designer benzodiazepines.  
4.1 DETECTION OF DESIGNER BENZODIAZEPINES USING 
IMMUNOCHEMISTRY 
The study in Paper I was performed to evaluate a number of commercial immunochemical 
assays for detection of designer benzodiazepines in urine.  
Paper I concluded that, using a 200 ng/mL cut-off, all compounds gave a response above the 
cut-off in the KIMS II assay when concentrations were ≤500 ng/mL, while for the CEDIA 
assay this was the case for all investigated compounds (Figure 6) except flutazolam. Whereas 
when using the EMIT II Plus and HEIA assays only 10 of the 13 investigated designer 
benzodiazepines had a response above the cut-off at the highest concentration investigated 
(1000 ng/mL).  
 
 
Figure 6: Chemical structure of the 13 benzodiazepines investigated in Paper I (re-printed 
from Paper I with permission). 
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In agreement with our study, Kyle et al [55] detected a mean cross-reactivity of 142% for 
phenazepam using the SIMENS EMIT II Plus assay (as compared to our 133%). They also 
performed studies of phenazepam using other immunoassays, showing cross-reactivities 
>80% in all but the enzyme linked immunosorbent assay (ELISA) [55]. Additionally, ELISA 
detection of phenazepam and other designer benzodiazepines (diclazepam, etizolam, 
flubromazepam and pyrazolam) has been studied in blood [56]. These authors concluded that 
the ELISA Immunalysis assay is sensitive enough to detect etizolam and pyrazolam in 
postmortem cases and that the benzodiazepines tested had a good cross-reactivity [56].  
When urine samples confirmed to contain pyrazolam were investigated using 
immunochemistry in Paper I, the concentration determinations from the LC-MS/MS analysis 
of the samples suggested presence of metabolites (due to a higher assay response than 
expected from the cross-reactivity experiments) although at that time none had been detected 
[52]. Consequently, we later performed a study to investigate the metabolic pattern of 
pyrazolam in human urine samples (Paper V). The results from this study (Paper V) 
confirmed presence of pyrazolam metabolites.  
None of the samples confirmed to contain only meclonazepam were detected in the HEIA 
assay, most likely due to the low parent concentrations found (Paper I) and since this assay 
has a low cross-reactivity of 7-aminometabolites [57] and Paper IV noted 7-amino-
meclonazepam as one of the major metabolites. Additionally, only one third of the urine 
samples confirmed to contain etizolam were detected using the HEIA assay, suggesting that 
not only the parent compound, but also the metabolites have a low cross-reactivity using this 
assay.  
Studies on the metabolic patterns of flubromazepam [16] and nifoxipam (Paper IV) indicated 
that the main metabolites found in urine are glucuronides. This is most likely the reason for 
the low reactivity of patient samples containing only one of these compounds in the EMIT II 
assay, since this assay generally has a low cross-reactivity of glucuronides and does not 
contain a reagent that can hydrolyze conjugates [58]. This is in agreement with the high 
detectability rate of patient samples with a confirmed intake of designer benzodiazepines in 
the immunoassays containing hydrolysis of the samples (CEDIA and KIMS II 
immunoassays).  
The good detectability of designer benzodiazepines in the CEDIA assay (Paper I) is 
somewhat different from the results obtained in self-ingestion experiments by the group of 
Auwärter [16, 17, 19, 52]. They could detect intake from self-ingestions of diclazepam, 
flubromazepam, flubromazolam and pyrazolam in urine samples, albeit only in one of the 
samples collected from ingestion of flubromazepam [16, 17, 19, 52]. Their calculated cross-
reactivity of diclazepam and flubromazepam was 136% and 79% in urine [16, 17], in 
comparison to our results in Paper I of 141% and 164%. One possible explanation for the 
differences obtained for flubromazepam might be variances between different lots, which has 
been noted as one of the drawbacks of immunoassay [30]. In serum samples obtained from 
the self-ingestions, only flubromazepam was detected [16, 17, 19, 52]. A low detectability 
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was also noted using the Fluorescence Polarization Immunoassay (FPIA) [16, 17, 52]. The 
reason for this could be the low doses ingested in the self-administration studies (only one 
tablet or capsule, apart from the case of pyrazolam where two tablets were ingested) [16, 17, 
19, 52]. 
The results from Paper I, in addition to previous studies [55, 56] showed that most designer 
benzodiazepines can be detected using commercially available immunoassays. Consequently, 
it is important to update confirmation methods to cover also these compounds, otherwise 
there is a risk of reporting “false” negative results.  
4.2 DETECTION OF DESIGNER BENZODIAZEPINES USING LIQUID 
CHROMATOGRAPHY MASS SPECTROMETRY 
To ensure a high quality in drug testing, efficient and sensitive methods are needed. Thus, we 
chose to use LC coupled to mass spectrometry when developing our detection methods for 
designer benzodiazepines (Paper II and III).  
In Paper II, our aim was to develop an LC-MS/MS method for the detection of designer 
benzodiazepines in urine and also to apply this method to urine samples sent to the laboratory 
for drug testing to obtain an indication of their occurrence in Sweden.  
An important step in assuring high quality methods for drug testing is validation of the 
method. In Paper II we applied the EMA guideline on bioanalytical method validation [54]. 
As this guideline focus on quantitation rather than qualification, additions were needed in 
order to enhance identification certainty. Therefore, an extra selected reaction monitoring 
transition (qualifier ion) per analyte investigated and a ratio between the ion transitions used 
for quantification and qualification was added [59]. Furthermore, to comply with the EMA 
guideline Paper II included rather extensive precision and accuracy experiments even though 
urine concentration determinations is less important since concentrations are dependent on 
many factors (e.g. urine pH and hydration status of the body) [60]. Due to these differences, 
drug testing in urine is by tradition only reported as either positive or negative (i.e. above or 
below a certain cut-off value). Recommendations of such cut-off values exists for some 
benzodiazepines [61], however these might not be suitable for designer benzodiazepines. 
Thus, by using a more thorough validation we would enhance the certainties of our 
concentration determinations and the results from our patient sample analysis could be used 
to set up cut-off values for drug testing of designer benzodiazepines.  
The method developed in Paper II included dilution of urine and enzymatic hydrolysis (10 
min), centrifugation (5 min) and injection directly into the LC-MS/MS system. As the total 
run time of the method was 4 min, the developed method is a fast way to analyze for designer 
benzodiazepine intoxication of the 11 benzodiazepines included in the method. A drawback 
of the method was that the CV (%) of the IS normalized matrix factor was not within the 
accepted values for clonazolam, flutazolam and nifoxipam.  
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When 390 patient urine samples that were screened positive with CEDIA and confirmed not 
to contain any prescription benzodiazepines were analyzed with the developed method, 40% 
were detected to contain at least one designer benzodiazepine. All designer benzodiazepines 
included in the method except diclazepam, flutazolam and phenazepam were detected. 
Phenazepam was, however, detected in samples from the STRIDA project. Additionally, 
amendment of urine drug testing cut-off values was demonstrated for several designer 
benzodiazepines (e.g. clonazolam, flubromazepam and meclonazepam) as many of these 
were found in concentrations lower than the cut-off value for benzodiazepines at our 
laboratory (50 ng/mL) (Paper II, Table 1).  
 
Table 1: Number of confirmed cases and concentration ranges found in the patient samples 
from Paper II (re-printed with permission from Paper II) 
Substance Concentration range (ng/mL) Number of samples (N) 
Pyrazolam 32-920 9 
Flubromazepam 2.7-30 14 
Meclonazepam 1.6-190 45 
Etizolam 5.8-270 11 
Nifoxipam 10-2800 4 
Deschloroetizolam 130 1 
Clonazolam 7.3-23 8 
Phenazepam 26-70 3* 
Flubromazolam 5.4-1500 96 
* These samples were obtained from the STRIDA project and are therefore not included in the 40% reported as positive 
designer benzodiazepine intoxications 
 
In conclusion, the method developed in Paper II was efficient and was able to detect intake 
of designer benzodiazepines in 40% of urine samples screening positive with CEDIA that 
were confirmed not to contain a prescription benzodiazepine. The high number of detected 
cases indicate a rather common use of designer benzodiazepines in Sweden, and the 
importance of including designer benzodiazepines in confirmation methods for drug testing.  
The aim of Paper III was to develop a sensitive and more flexible method for determination 
of designer benzodiazepines in urine that enables fast inclusion of new designer 
benzodiazepines appearing on the recreational drug market. This method was applied on 
urine samples from drug dependence clinics and acute intoxication cases suspected to involve 
NPS benzodiazepines (STRIDA samples).  
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To increase the identification certainty, both a screening method (LC–HRMS) and a 
confirmation method (LC–HRMS/MS) was developed. The screening method will enable 
fast inclusion of new analytes and retrospective investigation of already analyzed samples 
and will most likely result in less false positive screening result as compared to 
immunochemical assays, as has been noted in a previous study using drugs from different 
substance classes [62]. Also, this method is generic and could be applied to analysis of other 
drug classes as well. The confirmation method (LC–HRMS/MS) was developed to increase 
the certainty of the identification and is easily implemented since it only requires re-injection 
of samples with a positive result in the LC–HRMS screening method. Furthermore, since the 
sample preparation for the LC–HRMS method only included dilution of urine followed by 
hydrolysis (20 min) and the total run time was 5 min, screening of the urine samples will be 
fast.  
In Paper III, we performed a method validation using in-house guidelines instead of the 
EMA guideline. This was decided since three samples per QC level was deemed enough, 
however the between-run variability was determined over a longer time period as compared 
to Paper II to better reflect routine analysis work. The stability studies of Paper III was 
more extensive than in Paper II, as results from Paper II indicated a difference in analyte 
stability between different urines. The extensive stability experiments noted that nifoxipam 
was the most unstable analyte and using the obtained stability data, it is not recommended to 
store patient urine samples longer than one day at room temperature or one week at 4 °C. 
Stability experiments were not performed at -20 °C since extensive studies for nifoxipam had 
already been done at that temperature (Paper II) and our results from Paper III suggested 
that nifoxipam is the most unstable of the 28 analytes investigated. Carry-over was 
investigated for all analytes from injection of blank urine after injection of a standard 
containing 1000 ng/mL. The peak area in these blank urines were <20% of the LLOQ peak 
area for all anlytes in both the screening and the confirmation method, except for pyrazolam 
and tetrazepam. The blank urine peak areas of pyrazolam were always lower than the LLOQ 
peak area, while for tetrazepam a response similar to the peak area at the LLOQ level was 
detected. Due to this, it is recommended to re-analyze positive samples of tetrazepam if they 
have a concentration around LLOQ and were analyzed directly after a sample with a 
concentration around 1000 ng/mL. Again, the precision and accuracy experiments were 
rather extensive in Paper III as a result of our wish to use concentrations found in patient 
samples to determine suitable cut-off values for designer benzodiazepines in urine drug 
testing.  
When the developed screening and confirmation methods from Paper III was applied to 
analysis of patient samples from drug dependence clinics and from acute intoxication cases 
presenting in emergency wards 16 of the 28 benzodiazepines were detected. These included 
clobazam, clonazolam, deschloroetizolam, diclazepam, estazolam, etizolam, flubromazepam, 
flubromazolam, flunitrazolam, 3-hydroxyflubromazepam, 3-hydroxyphenazepam, ketazolam, 
meclonazepam, metizolam, nifoxipam, and pyrazolam. Also among these two sample sets a 
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rather high number (~30%) of cases were detected, again noting the importance of including 
designer benzodiazepines in drug testing analysis.  
 
Table 2: Concentration ranges found in Paper III in urine samples from drug dependence 
clinics (DDC) and from intoxication cases in emergency wards (STRIDA samples). 
Substance Concentration 
found in DDC 
samples 
(ng/mL) 
Number of 
DDC samples 
detected 
(N) 
Concentration 
found in 
STRIDA 
samples 
(ng/mL) 
Number of 
STRIDA 
samples 
detected  
(N) 
Clobazam 86 1 - - 
Clonazolam - - 10-132 9 
Deschloroetizolam - - 5 1 
Diclazepam - - 8 1 
Estazolam 30 1 8 1 
Etizolam - - 40-1000 5 
Flubromazepam 5 1 5-89 11 
Flubromazolam 15-61 6 5-1081 53 
Flunitrazolam 5-121 24 - - 
3-Hydroxy-
flubromazepam 
191-410 2 89-11580 10 
3-Hydroxy-
phenazepam 
84-16549 5 258-12089 5 
Ketazolam - - - 1 
Meclonazepam - - 5-126 10 
Metizolam 5-14 3 8 1 
Nifoxipam 149 1 973-3635 2 
Pyrazolam - - 6-1995 11 
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The results in Paper III confirmed results from Paper II showing that the 50 ng/mL cut-off 
value is too high for several of the designer benzodiazepines (e.g. clonazolam, 
flubromazepam, flunitrazolam, meclonazepam and metizolam, Table 2). On the other hand, 
for 3-hydroxyflubromazepam (a metabolite of flubromazepam [16]), the 50 ng/mL cut-off 
seems sufficient enough (Table 2), and thus our obtained LLOQ of 50 ng/mL is acceptable. 
An example of a patient sample from ingestion of flubromazepam is presented in Figure 7.  
 
 
 
Figure 7: Chromatograms from the screening method in Paper III showing a patient sample 
containing 7.4 ng/mL flubromazepam and 260 ng/mL 3-hydroxyflubromazepam (left) and a 
standard spiked at 5 ng/mL flubromazepam and 50 ng/mL 3-hydroxyflubromazepam (LLOQ 
levels of the analytes, right). 
 
In comparison to the method developed in Paper III, the method developed in Paper II and 
a GC-MS method developed by Meng et al for detection of four designer benzodiazepines in 
urine [37] had similar lower limit of quantification values (LLOQ). The GC–MS method was 
optimized for extraction of the four designer benzodiazepines included in the study, resulting 
in a faster extraction time than the hydrolysis times of our direct dilution methods [37]. 
However, a disadvantage of their method is the larger volume of urine (1mL) used in the 
sample preparation [37], as this would not be optimal in routine analysis work. Also, due to 
the extensive differences in polarity between different benzodiazepines [60] analysis of 
benzodiazepines with a lower lipophilicity might be difficult using their GC–MS method. 
Thus, our screening method developed in Paper III could be used instead since it allows fast 
inclusion of new analytes to the already existing method containing 28 benzodiazepines 
(Figure 8). Furthermore, the combined screening and confirmation method developed in 
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Paper III has the advantage of fast screening of an unlimited number of analytes for which a 
confirmation can be performed directly after the screening result on the same instrument by 
only re-injecting the sample.  
 
 
Figure 8: Chromatograms showing the retention time (RT) of all analytes included in Paper 
III in a screening method run of the highest standard (1,000 ng/mL). Ketazolam is here 
shown as both M+H
+
 ion (RT 2.67) and its in-source fragment at m/z 285.0789 (RT 2.66). 
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Another study investigating the detection of designer benzodiazepines in blood also used 
HRMS as a mean for fast inclusion of new analytes to the detection method [34]. This study 
included both a targeted and an untargeted approach based on another HRMS technique 
coupled to a quadrupole [34]. One advantage of this method is that it uses an HRMS mode 
that allows obtaining MS/MS spectra without previously determining the parent ions used for 
recording the spectra [34]. However, since spectra are obtained simultaneously from several 
incoming ions, sensitivities of such methods are usually lower than for the ones where a 
parent ion is predetermined. Thus, for detection of compounds where a low amount is 
expected in the sample (as is the case of several designer benzodiazepines, Paper II and III), 
an approach with a predetermined parent ion would be preferable.  
In summary, the LC–HRMS(/MS) method developed in Paper III offered sensitive detection 
of a large number of benzodiazepines. It can be used for fast screening and confirmation of 
benzodiazepine intake by simply preparing the sample once and it enables easy inclusion of 
new analytes. When applied to urine samples from drug dependence clinics and acute drug 
intoxication cases, it revealed a high prevalence (~30%) of designer benzodiazepine use, thus 
underlining the importance of including these benzodiazepines in urine drug testing. This 
prevalence number was similar to our previous study. When patient sample results from 
Paper II and Paper III were combined, ~38% of patient samples from drug dependence 
clinics that were positive in the CEDIA assay and confirmed not to contain prescription 
benzodiazepines instead contained designer benzodiazepines. 
4.3 METABOLIC PATTERNS OF DESIGNER BENZODIAZEPINES 
Both low resolution MS [16-21, 52] and HRMS (Paper IV, V) [16, 18-20, 22-27, 52] have 
been used to determine the metabolic pattern of designer benzodiazepines, and as mentioned 
in 1.5.3, the advantage of using HRMS is the ability to determine elemental compositions of 
unknown substances, resulting in more reliable interpretations in metabolite structure 
elucidations. Thus, both metabolic studies included in this thesis (Paper IV, V) were 
performed using HRMS.  
The aim of Paper IV was to determine the metabolic patterns of clonazolam, meclonazepam 
and nifoxipam in humans by analyzing analytically confirmed intoxication cases. 
Furthermore, these results were used to determine suitable targets for urine drug testing. 
Most recent studies of designer benzodiazepine metabolism have entailed analysis of the 
samples using LC-MS with electrospray ionization [16-27, 52]. As mentioned in section 
1.5.3, there is a risk of large matrix effects that then would lead to a misinterpretation of the 
relative amount of metabolites present in the sample due to differences in ionization 
efficiency. In order to minimize this effect, we instead performed the analyses in Paper IV 
using using a low flow variant, nano-electrospray ionization (NSI). One reason to use NSI 
was the concept that the chromatogram peak areas correspond better with concentration 
values as compared to ESI [63, 64]. It has been suggested that this would be due to the 
smaller initial droplet sizes obtained in NSI compared to ESI, which would lead to lower 
  23 
amount of break downs necessary for ionization. This would then result in smaller matrix 
effects due to reduction of the amount species present for ionization and thus provide peak 
areas that better correspond to actual concentration [64]. Another advantage of the 
instrumental step up used in Paper IV is the use of nano-LC coupled to NSI that, in theory, 
would result in improved separation efficiency and increased sensitivity compared to 
conventional UHPLC because of the lower inner diameters used in nano-LC (1.5.2). 
Our studies in Paper IV using NSI underlined the need to involve metabolites of clonazolam, 
meclonazepam and nifoxipam to allow reliable drug testing of these compounds since the 
abundance of the parent compound was low compared with the acetamino and amino 
metabolites (Figure 9). Based on the relative abundance between the metabolites in several 
analytically confirmed intoxication cases (Figure 9), 7-aminoclonazolam, 7-acetamino-
meclonazepam and nifoxipam glucuronide seems to be the most abundant metabolites.  
Apart from human in vivo studies in our Paper IV and a later study [22], metabolism studies 
of meclonazepam have included in vitro studies in HLM, HLM combined with HLC, s9 and 
hepatocytes [20-23] and in vivo studies using mouse urine [22]. Results using only HLM 
detected a hydroxy metabolite [20] and reduction of the nitro group [20-22]. When 
incubations of HLM were combined with HLC, an acetamino metabolite, in addition to the 
previously mentioned metabolites, was detected [23]. This was also the case when s9 
fractions were used [23].  
Using hepatocytes, Vikingsson et al [22] confirmed the metabolites (amino and acetamino) 
we detected in Paper IV, using urine samples from analytically confirmed ingestions of 
meclonazepam. Furthermore, their study detected 13 candidate metabolites of meclonazepam 
using urine from paired blood samples with confirmed meclonazepam intake. However, mass 
spectra could only be obtained for the amino and acetamino metabolites. As a result, the 
certainties in chemical structure of the rest of the metabolites are lower. Furthermore, apart 
from the amino and acetamino metabolites only one additional metabolite (monohydroxy 
acetaminometabolite) was detected in mouse urine [22]. This imply that the main targets in 
urine testing should be the amino and acetamino metabolites, which confirm our previously 
reported suggestions from Paper IV. It has been suggested [22] that the reason the acetamino 
metabolite was not detected when incubations were performed only with HLM were that it is 
likely that this metabolite is formed by the cytosolic enzyme NAT2, as in the case of 
clonazepam.  
The other study using human urine samples [22] had higher area ratios for the amino 
metabolite in three of their four investigated urine cases, while in our previous study with 
NSI (Paper IV) the area was higher for the acetamino metabolite in four of seven cases 
(Figure 9). Authors of the other meclonazepam study suggested that their detected differences 
in ratio between the amino and acetamino metabolites could be due to polymorphism of 
NAT2 [22]. However, as the matrix effects cannot be evaluated due to lack of reference 
material, the matrix effects could also be the reason for the differences. Furthermore, as the 
acetamino metabolite is a conjugated metabolite of the aminometabolite, variance in intensity 
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might also derive from differences in time between ingestion and sampling. On the other 
hand, as the patient samples collected from the STRIDA project are collected from patients 
presenting in emergency wards a sampling close to ingestion can be assumed. The results 
from the relative distribution of the parent compound and the metabolites in the STRIDA 
samples (Figure 9, individual no 3–5) suggest that the conjugation of the aminometabolite to 
the acetaminometabolite is rather fast. 
 
Figure 9: Relative areas (%) of clonazolam, meclonazepam, nifoxipam and metabolites 
compared to the total area of all analytes in the samples. STRIDA samples are marked with 
an asterix (re-printed from Paper IV with permission). 
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To conclude, as the metabolites of meclonazepam had a higher peak area compared to the 
parent compound in two separate investigations, Paper IV and [22], these metabolites can 
therefore be considered suitable targets for urine drug testing. The most abundant analytes in 
our NSI studies using cases from several analytically conformed intoxication cases were 7-
aminoclonazolam, 7-acetaminomeclonazepam and nifoxipam glucuronide. Thus, urine drug 
testing should focus on these three metabolites rather than, or in addition to, the parent 
compound. On the other hand, as nifoxipam is a metabolite of flunitrazepam [65] caution 
must be taken when interpreting such results even though both nifoxipam and its metabolites 
are present in the sample. 
The aim of Paper V was to further investigate the metabolic pattern of flubromazolam and 
pyrazolam and recommend suitable targets for urine drug testing by analyzing several urine 
samples from analytically confirmed intoxication cases.  
A method validation was performed in Paper V as we wanted to compare the concentrations 
of parent compound in our study samples using a sample preparation with and without 
hydrolysis. Since the metabolic pattern studies were the focus of Paper V, the validation was 
not as extensive as in Paper II and III. Matrix effects were ≤16% at the two investigated 
concentration levels for both sample preparation methods applied in Paper V, suggesting 
only minor interferences in ionization of the parent compounds from other components 
present in the sample. 
Extensive metabolic investigations have been performed for flubromazolam (Paper V) [19-
21, 24, 25]. The HLM studies of flubromazolam detected mono hydroxy metabolites [20, 21, 
25], di-hydroxy metabolites [20, 21, 25], hydroxy glucuronides [25] and a parent glucuronide 
[25]. However, one of the in vitro studies could not detect any metabolites in HLM and only 
small signals of two hydroxy metabolites in hepatocytes [24]. The same study could on the 
other hand detect several metabolites (hydroxy metabolites, di-hydroxy metabolites, hydroxy 
glucuronides, di-hydroxy glucuronides and parent glucuronides) in vivo in urine samples 
from mice [24]. Furthermore, several studies have been performed using urine samples from 
analytically confirmed intoxication cases (Paper V) [19, 24, 25]. Only one study could detect 
a low signal of a di-hydroxy metabolite in these cases [24], noting the importance of 
confirming results from HLM studies using human urine samples. In the results published 
from human urine samples, two hydroxy metabolites, at least one hydroxy glucuronide and at 
least one parent glucuronide have been detected (Figure 10, Paper V) [19, 24, 25].  
Hydrolysis of the urines samples was recommended due to the high abundance of 
glucuronides (Figure 10, Paper V) [19, 24]. The advantage of hydrolyzing urine samples 
during investigations of flubromazolam intake was confirmed in Paper V, where it was 
shown that the concentrations of flubromazolam increased as much as 2–19 fold when 
hydrolysis was applied. If hydrolysis is performed, a hydroxy metabolite together with the 
parent compound should be used as targets in urine drug testing. If no hydrolysis is applied, 
the best targets for drug testing are parent compound together with a parent glucuronide 
and/or a hydroxy glucuronide.  
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Figure 10: Relative areas (%) of flubromazolam and metabolites compared to the total area 
of all analytes in the samples without hydrolysis and with hydrolysis (re-printed from Paper 
V with permission). 
 
The first metabolic study of pyrazolam did not detect any metabolites neither in HLM nor in 
samples from self-administration studies [52]. As mentioned previously, due to the results 
obtained in Paper I suggesting the presence of metabolites, we performed a confirmation 
study using urine samples from several analytically confirmed intoxication cases. Our results 
in Paper V contradicted these previous data as phase I hydroxy metabolites and glucuronide 
conjugates of both the parent compound and the phase I metabolites were found (Figure 11). 
Possible reasons for the differences include inter-individual excretion patterns and dose 
differences between the self-ingestion study and consumed amount by patients using the 
drug. Also, even though metabolites of pyrazolam were detected, their relative intensities 
were much lower in the patient samples as compared to the parent compound (both with and 
without hydrolysis). Although ESI was used as an ionization technique in this study and the 
estimated abundances of the metabolites might be highly affected by matrix effects, no 
significant increase in parent concentration was detected after hydrolysis was performed. For 
pyrazolam, if hydrolysis is not performed, either parent glucuronide and parent compound or 
only parent compound should be used as bioanalytical targets in urine drug testing. When 
hydrolysis is applied, the parent compound and a hydroxy metabolite are the best targets.  
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Figure 11: Proposed metabolic pathway of pyrazolam. Main targets in drug testing include 
parent compound and parent glucuronide (without hydrolysis) or parent compound and 
hydroxy metabolite isomer 2 (with hydrolysis). 
 
In summary, Paper V noted that flubromazolam samples should be hydrolyzed before urine 
analysis in order to increase detection of both parent compound and phase I metabolites. 
Good targets for urine drug testing in such cases are parent compound and a hydroxy 
metabolite. For pyrazolam hydrolysis is not necessary due to the high parent concentration 
and a good additional target to increase the certainties of the identification is the parent 
glucuronide. 
4.4 PREVALENCE OF DESIGNER BENZODIAZEPINES IN SWEDEN 
The aim of Paper VI was to study the occurrence of designer benzodiazepines in Sweden, 
investigate patterns of abuse among designer benzodiazepine users (in relation to multi-
intoxications and time of national legislation) and to investigate clinical features of designer 
benzodiazepines. This was performed by analyzing patient samples collected from 
intoxicated patients admitted to hospitals due to exposure of NPS or unknown drugs.  
The study in Paper VI was made possible due to the highly selective methods developed in 
Paper II and III. Among the 1913 urine samples investigated in Paper VI, from patients 
presented to hospitals for emergency treatment from 2012 to 2016, 11% were confirmed to 
contain a designer benzodiazepine. The most common designer benzodiazepine detected 
was flubromazolam (detected in 42% of all designer benzodiazepine intoxications, Figure 
12). In most cases, the designer benzodiazepines disappeared from the market after they 
became classified as narcotics in Sweden (Figure 12).  
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Furthermore, designer benzodiazepines were mostly ingested together with substances from 
other classes (stimulants, depressants and mixtures from several classes of drugs at 11, 29 
and 50%, respectively). A large co-ingestion of designer benzodiazepines and prescription 
benzodiazepines was detected and as much as around one third of all investigated samples 
contained a prescription benzodiazepine. Unfortunately, as there was no standardization of 
written documentation or sampling time, it has not been possible to distinguish whether this 
derived from benzodiazepine treatment in critical care or misuse. Also, as some designer 
benzodiazepines are metabolites of prescription benzodiazepines or other designer 
benzodiazepines [66, 67] this complicates the bioanalytical investigations. One might also 
argue that since our detection method mostly target designer benzodiazepine parent 
compounds and not metabolites, many cases could probably go undetected due to the 
variation in sampling time. This could especially be the cases for diclazepam, clonazolam 
and meclonazepam intoxications, where low parent concentrations have been reported 
(Paper II, III) [17]. 
In agreement with our results from Paper VI (noting a large co-ingestion of designer 
benzodiazepines with prescription benzodiazepines), a study using driving under the 
influence of drugs (DUID) samples detected amphetamines and prescription 
benzodiazepines as the most common substances ingested with phenazepam [68]. The same 
study detected phenazepam in 3.5% of all positive DUID cases, however no cases were 
detected in workplace drug testing. Moreover, another larger study using samples from 
various criminal offenders (e.g. DUID cases) detected 0.3% designer benzodiazepines 
among the >22 000 cases investigated [35]. Again, this study demonstrated a large co-
ingestion of prescription benzodiazepines (present in 66% of the designer benzodiazepine 
intoxications where other drugs were detected as well) and designer benzodiazepines [35]. 
A study with samples from nightclub patrons detected etizolam and phenazepam in oral 
fluid samples, however no data regarding co-ingestions was reported [36]. The cases found 
in these three studies (all performed in Nordic countries) demonstrated a much lower 
prevalence of designer benzodiazepines than our 11%. As our sample set is based on 
suspected intake of NPS presenting to hospitals, this might be the reason for the higher 
prevalence of designer benzodiazepines found in our study or it could also derive from a 
higher occurrence in Sweden in general as compared to other Nordic countries. 
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Figure 12: Cases testing positive for designer benzodiazepines in the STRIDA project from 
2012 to 2016. Black bars represent a suspicion or claimed exposure to any benzodiazepine 
(BZD), and arrows represent the time for classification (*substances banned before the start 
of the study). 
 
The main clinical sign detected in patients exposed only to designer benzodiazepines in our 
study was central nervous system (CNS) depression and the benzodiazepine antidote 
flumazenil was proven useful for severe intoxications. Furthermore, when analyzing the data 
from cases confirmed to only contain designer benzodiazepines, flubromazolam was 
indicated as especially hazardous since two of the three most severe ill patients had a 
confirmed flubromazolam intake. This agrees with a previously reported case study where a 
patient needed hospital treatment for several days [38].  
In summary, designer benzodiazepines were detected in 11% of intoxication cases 
presenting in emergency wards in Sweden from 2012 to 2016 and most of these were 
multiple intoxications. Intoxications using designer benzodiazepines may result in CNS 
depression that can be treated using the benzodiazepine antagonist flumazenil. As most of the 
designer benzodiazepines investigated in Paper VI disappeared from the recreational drug 
market after being classified as narcotic substances, one might consider changing the 
classification system in Sweden from an individual listing system to one of the two other 
main systems (the generic or the analogue laws) applied for NPS [8].  
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5 CONCLUSIONS 
Frequent use of designer or NPS benzodiazepines was demonstrated in Sweden, both from 
studies of urine samples from drug dependence units submitted for drug testing and samples 
from acute intoxication cases at hospitals. The following main conclusions can be drawn: 
 Most designer benzodiazepines showed good cross-reactivity in commercial 
immunoassays targeting prescription benzodiazepines in urine samples. 
 LC–MS methods for analysis of designer benzodiazepines in urine can be 
developed using a simple direct dilution approach followed by hydrolysis of 
conjugated forms prior to injection into the LC–MS system. 
 In cases where laboratories have access to LC–HRMS, screening using diluted 
hydrolyzed urine samples injected directly into the LC–HRMS system combined 
with re-injection of positive cases in LC–HRMS/MS mode is an alternative to 
immunoassay screening followed by LC–MS confirmation. 
 Metabolic patterns of the designer benzodiazepines clonazolam, flubromazolam, 
meclonazepam, nifoxipam and pyrazolam corresponded to those of prescription 
benzodiazepines, including e.g. hydroxylation, glucuronidation and, for 
compounds containing a nitro group, nitro reduction followed by acetylation.  
 Parent compounds are generally suitable analytical targets in urine drug testing for 
designer benzodiazepines, except when containing a nitro group, where suitable 
targets instead are the amino and acetamino metabolites. 
 Designer benzodiazepine use was indicated to be rather common in Sweden. About 
38% of urine samples from drug dependence units showing positive immunoassay 
screening result but confirmed not to contain prescription benzodiazepines were 
demonstrated to instead contain designer benzodiazepines. 
 Intoxication by designer benzodiazepines may result in central nervous system 
depression that can be treated using flumazenil. 
 Designer benzodiazepines generally disappeared from the recreational drug market 
after being classified as narcotic substances but were replaced by novel variants. 
Consequently, it is important to include new designer benzodiazepines in bioanalytical 
drug testing methods and to continuously update these detection methods.  
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